Organisation paid for research Program year 2025 Source: CMS Open Payments

Dana-Farber/ Mass General

Neither a doctor nor a teaching hospital

Research payments

$1,975,333

103 payments

Through program year 2025, Dana-Farber/ Mass General is reported as receiving $1,975,333 in research payments, across 103 payments.

By program year

2 rows

Year	Kind	Amount	Payments
2025	Research	$1,661,489	95
2024	Research	$313,844	8

Breakdown

Who paid Research payments · program years 2024–2025

Incyte Corporation $1,975,333 103 payments

Studies the money was for Research payments · program years 2024–2025

Phase II study of Ruxolitinib in Low RiskEssential Thrombocythemia and PolycythemiaVera with significant symptom burdens $702,280 2 payments
Proof of Concept trial of Axatilimab with Olaparib in BRCA-associated breast cancer $332,340 6 payments
A Phase 1, Open-Label, Multicenter Study of INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation $299,347 55 payments
Phase II study of Ruxolitinib in Low RiskEssential Thrombocythemia and PolycythemiaVera with significant symptom burdens $252,670 3 payments
A Phase Ia/Ib Study of the Combination of the FGFR inhibitor Pemigatinib and the EGFR inhibitor Afatinib in AdvancedRefractory Advanced Solid Tumors $244,201 7 payments
Proof of Concept trial of Axatilimab with Olaparib in BRCA-associated breast cancer $47,524 1 payment
A Phase 1, Open-Label, Multicenter Study of INCA33890 in Participants With Advanced or Metastatic Solid Tumors $43,525 9 payments
A Phase 1, Open-Label, Multicenter Study of INCA033989 in Participants With Myeloproliferative Neoplasms $23,447 10 payments
A phase II study of ruxolitinib for bronchiolitis obliterans syndrome (BOS) after allogeneic hematopoietic cell transplantation (HCT) $13,650 4 payments
A Phase 1a/1b Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced Malignancies $7,223 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.